ȸ»ç¼Ò°³
|
¹®ÀÇ
|
À§½Ã¸®½ºÆ®
½ÃÀåÁ¶»çº¸°í¼
ÀÚµ¿Â÷
Åë½Å/IT
ÀüÀÚºÎǰ/¹ÝµµÃ¼
¿¡³ÊÁö/ȯ°æ
ÀǾàǰ
ÀÇ·á±â±â
¹æÀ§/Ç×°ø/¿ìÁÖ
¸ÅÆ®¸®¾ó
½Äǰ/À½·á
»ê¾÷¿ë±â°è
ÀϹݼҺñÀç
ÀÎÇÁ¶ó
±ÝÀ¶/¹ðÅ·
¿¬°£Á¤º¸¼ºñ½º
¸ÂÃãÇü½ÃÀåÁ¶»ç
±Û·Î¹úÆÄÆ®³Ê
¸ÞÀϸµ¼ºñ½º
My Cart
Ȩ
>
±Û·Î¹ú ÆÄÆ®³Ê
> La Merie Publishing
Ä«Å×°í¸®
±Û·Î¹ú ÆÄÆ®³Ê
ÀÚµ¿Â÷
Åë½Å/IT
ÀüÀÚºÎǰ/¹ÝµµÃ¼
¿¡³ÊÁö/ȯ°æ
ÀǾàǰ
ÀÇ·á±â±â
¹æÀ§/Ç×°ø/¿ìÁÖ
¸ÅÆ®¸®¾ó
½Äǰ/À½·á
»ê¾÷¿ë±â°è
ÀϹݼҺñÀç
ÀÎÇÁ¶ó
±ÝÀ¶/¹ðÅ·
La Merie Publishing
½ºÆäÀÎ ¹Ù¸£¼¿·Î³ª¿¡ º»»ç¸¦ µÐ La Merie´Â ¹ÙÀÌ¿À Å×Å©³î·¯Áö ¹× Á¦¾à »ê¾÷¿¡ ´ëÇÑ ¸®¼Ä¡¸¦ Àü¹®À¸·Î Çϰí ÀÖ½À´Ï´Ù.
Á¦¸ñ °Ë»ö
1
-
25
¸®ºä (Àüü£º
27
°Ç)
Á¤·Ä
¹ßÇàÀÏ
ÇѱÛÁ¦¸ñ
¿µ¹®Á¦¸ñ
°¡°Ý
Ç¥½Ã °Ç¼ö
25
50
100
1
2
´ÙÀ½
½Å¾à R&D ÆÄÀÌÇÁ¶óÀÎ µ¥ÀÌÅͺ£À̽º : ¿¬°£ ±¸µ¶
R&D Drug Pipeline Database: 1-Year Subscription
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
302689
¹ßÇàÁ¤º¸
¿¬°£±¸µ¶
ÆäÀÌÁö Á¤º¸
°¡°Ý
US $ 7,400 ->
£Ü 8,883,000
RNA Ç¥Àû ÀúºÐÀÚ(2019³â) : ±â¾÷, ±â¼ú, ¸ñÇ¥, ÅõÀÚ°¡, ÆÄÆ®³Ê·ÎºÎÅÍÀÇ ¾÷°è Àü¸Á
RNA-Targeted Small Molecules 2019: A Landscape Analysis of Companies, Technologies, Targets, Investors and Partners from an Industry Perspective
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
911032
¹ßÇà
2019³â 09¿ù
ÆäÀÌÁö Á¤º¸
223 Pages
°¡°Ý
US $ 2,350 ->
£Ü 2,821,000
°æÀï»ç ºÐ¼® : ¾Ï¸é¿ª ¹× ±âŸ ÁúȯÀ» À§ÇÑ ÀÌÁß Æ¯À̼º Ç×ü
Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
890224
¹ßÇà
2019³â 06¿ù
ÆäÀÌÁö Á¤º¸
125 Pages
°¡°Ý
US $ 900 ->
£Ü 1,080,000
º¸°í¼ ÆÐŰÁö - °æÀï»ç ºÐ¼® : ¾Ï¸é¿ª ¹× ±âŸ ÁúȯÀ» À§ÇÑ ÀÌÁß Æ¯À̼º Ç×ü, T¼¼Æ÷ ¹× NK(ÀÚ¿¬»ìÇØ)¼¼Æ÷¿Í °áÇÕÇÏ´Â ÀÌÁ߯¯À̼º Ç×ü(2019³â) : ºñÁö´Ï½º, ÀÌÇØ°ü°èÀÚ, ±â¼ú ¹× ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
2 Reports Bundle - Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases plus T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: A Business, Stakeholder, Technology and Pipeline Analysis
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
890416
¹ßÇà
2019³â 06¿ù
ÆäÀÌÁö Á¤º¸
°¡°Ý
US $ 2,840 ->
£Ü 3,409,000
T¼¼Æ÷ ¹× NK(ÀÚ¿¬»ìÇØ)¼¼Æ÷¿Í °áÇÕÇÏ´Â ÀÌÁ߯¯À̼º Ç×ü(2019³â) : ºñÁö´Ï½º, ÀÌÇØ°ü°èÀÚ, ±â¼ú ¹× ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: A Business, Stakeholder, Technology and Pipeline Analysis
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
868394
¹ßÇà
2019³â 06¿ù
ÆäÀÌÁö Á¤º¸
463 Pages
°¡°Ý
US $ 2,700 ->
£Ü 3,241,000
°æÀï»ç ºÐ¼® : ¾Ï ¸é¿ªÄ¡·á¿¡¼ÀÇ ¾ïÁ¦¼º¡¤Àڱؼº ¸é¿ªÁ¶ÀýÁ¦(º¸°í¼ 4±Ç ¼¼Æ®)
4 Reports Bundle: Immuno-Oncology - Inhibitory and Stimulatory Immunomodulators
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
408112
¹ßÇà
2018³â 07¿ù
ÆäÀÌÁö Á¤º¸
455 Pages
°¡°Ý
US $ 1,690 ->
£Ü 2,028,000
MAGE-A, NY-ESO-1, hTERT, WT1, PRAME, ¼¹ÙÀ̺óÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ¸é¿ª¿ä¹ý : º¸°í¼ 6±Ç ¼¼Æ®
6 Reports Bundle: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
651129
¹ßÇà
2018³â 06¿ù
ÆäÀÌÁö Á¤º¸
°¡°Ý
US $ 955 ->
£Ü 1,146,000
T¼¼Æ÷ ¼ö¿ëü(TCR) ±â¹Ý Ç×ü ¹× T¼¼Æ÷ ¸é¿ª¿ä¹ý : º¸°í¼ 2±Ç ¼¼Æ®
2 Reports Bundle: TCR-Based Antibody and T-Cell Immunotherapy
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
651128
¹ßÇà
2018³â 05¿ù
ÆäÀÌÁö Á¤º¸
°¡°Ý
US $ 3,505 ->
£Ü 4,207,000
T¼¼Æ÷ ¼ö¿ëü Á¶ÀÛ T¼¼Æ÷ Ä¡·á¹ý(2018³â) : ±â¼ú, ÆÄÀÌÇÁ¶óÀÎ, ÀÌÇØ°ü°èÀÚ, °è¾àÀÇ »ê¾÷ ºÐ¼®
TCR Engineered T-Cell Therapy 2018: An Industry Analysis of Technologies, Pipelines, Stakeholders & Deals
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
642119
¹ßÇà
2018³â 05¿ù
ÆäÀÌÁö Á¤º¸
294 Pages
°¡°Ý
US $ 2,500 ->
£Ü 3,001,000
TCR À¯»ç Ç×ü, TCR À¶ÇÕ ´Ü¹éÁú, ¼¼Æ÷ Åõ°ú¼º »ý¹°Á¦Á¦¿¡ ÀÇÇØ ÀǾàǰÀÌ µÉ¸¸ÇÑ ¼¼Æ÷³» Ç¥Àû : »ê¾÷ ºÐ¼®
Intracellular Targets Made Druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: An Industry Analysis of Technologies, Stakeholders, Deals & Trends
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
600758
¹ßÇà
2018³â 01¿ù
ÆäÀÌÁö Á¤º¸
251 Pages
°¡°Ý
US $ 2,800 ->
£Ü 3,361,000
°æÀï»ç ºÐ¼® : ¾Æ¹Ù½ºÆ¾(Avastin), »çÀ̶÷ÀÚ(Cyramza), ¾ÆÀϸ®¾Æ(Eylea), ·ç¼¾Æ¼½º(Lucentis)ÀÇ Ç×VEGF, Ç×VEGF-R ¹ÙÀÌ¿À½Ã¹Ð·¯ ¹× ¹ÙÀÌ¿À¼öÇǸ®¾î
Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - 2017 Update
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
358307
¹ßÇà
2017³â 11¿ù
ÆäÀÌÁö Á¤º¸
58 Pages
°¡°Ý
US $ 525 ->
£Ü 630,000
º¸°í¼ ÆÐŰÁö : ¾Ï ¿ëÇØ¼º ¹ÙÀÌ·¯½º¿¡ ÀÇÇÑ ¸é¿ªÄ¡·á¿Í mRNA ¹é½Å ¹× Ä¡·áÁ¦
2 Reports Bundle: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
579795
¹ßÇà
2017³â 10¿ù
ÆäÀÌÁö Á¤º¸
°¡°Ý
US $ 3,600 ->
£Ü 4,321,000
mRNA ¹é½Å ¹× Ä¡·áÁ¦ : »ê¾÷ ºÐ¼®(±â¼ú, ÆÄÀÌÇÁ¶óÀÎ, ÀÌÇØ°ü°èÀÚ, °Å·¡)
mRNA Vaccines & Therapeutics 2017: An Industry Analysis of Technologies, Pipelines, Stakeholders and Deals
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
518829
¹ßÇà
2017³â 06¿ù
ÆäÀÌÁö Á¤º¸
260 Pages
°¡°Ý
US $ 2,520 ->
£Ü 3,025,000
¾Ï ¿ëÇØ¼º ¹ÙÀÌ·¯½º : ÆÄÀÌÇÁ¶óÀÎ, ÀÌÇØ°ü°èÀÚ, °Å·¡, »ê¾÷ µ¿Çâ ¹× ±âȸ ºÐ¼®
The Oncolytic Virus Landscape 2017: An Analysis of Pipeline, Stakeholders, Deals, Industry Trends & Opportunities
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
425869
¹ßÇà
2017³â 01¿ù
ÆäÀÌÁö Á¤º¸
225 Pages
°¡°Ý
US $ 2,400 ->
£Ü 2,881,000
°È Ç×ü ¹× ¼¼Æ÷ Ä¡·á ±â¼úÀÇ ÁÖ¸ñ Ç¥Àû(º¸°í¼ 3±Ç ¼¼Æ®)
3 Reports Bundle: Hot Targets for Empowered Antibody and Cell Therapy Technologies
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
408113
¹ßÇà
2016³â 12¿ù
ÆäÀÌÁö Á¤º¸
202 Pages
°¡°Ý
US $ 1,254 ->
£Ü 1,505,000
º¸°í¼ ¼¼Æ® : ÀÌÁ߯¯À̼º Ç×ü¿¡ ÀÇÇÑ T¼¼Æ÷ ¸é¿ª¿ä¹ý ¹× CAR & TCR ÀçÁ¶ÇÕ T¼¼Æ÷
2 Reports Bundle: T-Cell Immunotherapy by Bispecific Antibodies and CAR & TCR Engineered T-Cells (Two Reports released in 2016)
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
368816
¹ßÇà
2016³â 09¿ù
ÆäÀÌÁö Á¤º¸
°¡°Ý
US $ 3,400 ->
£Ü 4,081,000
CD123 : ¸é¿ª¿ä¹ýÀÇ °è¿Àû Ç¥Àû
CD123: A Paradigmatic Target for Immunotherapeutic Treatment Modalities
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
369010
¹ßÇà
2016³â 08¿ù
ÆäÀÌÁö Á¤º¸
83 Pages
°¡°Ý
US $ 800 ->
£Ü 960,000
B¼¼Æ÷ ¼º¼÷È Ç׿ø(BCMA) : »õ·Î¿î Ä¡·á¹ý Ç¥Àû
B-Cell Maturation Antigen (BCMA): Hot Target for Emerging Treatment Modalities
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
369011
¹ßÇà
2016³â 08¿ù
ÆäÀÌÁö Á¤º¸
39 Pages
°¡°Ý
US $ 570 ->
£Ü 684,000
TCR&CAR °³º¯ T¼¼Æ÷ ¹× NK ¼¼Æ÷ Ä¡·á(2016³â) : °¢Á¾ ±â¼ú ÄÁ¹öÀü½º¿¡ ÀÇÇÑ CD19 CART ÀÌ¿ÜÀÇ »õ·Î¿î ½ÃÀå ±âȸ
TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of Technologies Opens Business Opportunities Beyond CD19 CARTs
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
366651
¹ßÇà
2016³â 08¿ù
ÆäÀÌÁö Á¤º¸
388 Pages
°¡°Ý
US $ 2,750 ->
£Ü 3,301,000
¹ÙÀÌ¿À½Ã¹Ð·¯ ¹× ¹ÙÀÌ¿À¼öÇǸ®¾î Ä¡·á¿ë Ç×üÀÇ °æÀï ºÐ¼®
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
327820
¹ßÇà
2016³â 05¿ù
ÆäÀÌÁö Á¤º¸
462 Pages
°¡°Ý
US $ 1,450 ->
£Ü 1,740,000
T¼¼Æ÷ ¸®´ÙÀÌ·ºÆÃ ÀÌÁß Æ¯À̼º Ç×ü : ÀÌÇØ°ü°èÀÚ, ±â¼ú, ÆÄÀÌÇÁ¶óÀÎ, °Å·¡ÀÇ °æÀï ±¸µµ ºÐ¼®
T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
357780
¹ßÇà
2016³â 05¿ù
ÆäÀÌÁö Á¤º¸
230 Pages
°¡°Ý
US $ 2,400 ->
£Ü 2,881,000
·¹Æ¼³ë»ê °ü·Ã °í¾Æ ÇÙ¼ö¿ëü °¨¸¶(ROR¥ã) Á¶ÀýÀÎÀÚ : ROR¥ã ±æÇ×Á¦¿Í ÀÛ¿ëÁ¦ÀÇ »óȲ ºñ±³ ºÐ¼®
RORgamma Modulators 2016: A Comparative Analysis of the Landscape of RORgamma Antagonists and Agonists
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
351304
¹ßÇà
2016³â 02¿ù
ÆäÀÌÁö Á¤º¸
88 Pages
°¡°Ý
US $ 1,050 ->
£Ü 1,260,000
Ç×ü¾à¹°°áÇÕü(ADC) Àü¸Á ¹× ½ÃÀå ±âȸ : ÆÄÀÌÇÁ¶óÀÎ, ±â¼ú, ÀÌÇØ°ü°èÀÚ ¹× ºñÁö´Ï½º ºÐ¼®(2016³â)
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - A Pipeline, Technology, Stakeholder & Business Analysis
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
294276
¹ßÇà
2015³â 11¿ù
ÆäÀÌÁö Á¤º¸
470 Pages
°¡°Ý
US $ 2,500 ->
£Ü 3,001,000
ÀçÁ¶ÇÕ T¼¼Æ÷ ¼ö¿ëü(TCR) ¹× Ű¸Þ¶ó Ç׿ø ¼ö¿ëü(CAR) ¸é¿ªÄ¡·á(2015³â)
Engineered TCR and CAR Immunotherapeutics 2015
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
325905
¹ßÇà
2015³â 03¿ù
ÆäÀÌÁö Á¤º¸
201 Pages
°¡°Ý
US $ 2,630 ->
£Ü 3,157,000
ÀçÁ¶ÇÕ Ç÷¾×ÀÀ°íÀÎÀÚ : ÀçÁ¶ÇÕ ÀÀ°íÀÎÀÚ ÆÄÀÌÇÁ¶óÀÎÀÇ ¼º¼÷°ú À¯ÀüÀÚ Ä¡·á ¹× ´ëü ÀÀ°íÃËÁøÁ¦ÀÇ µîÀå
Recombinant Coagulation Factors 2015: Maturation of Recombinant Clotting Factor Pipeline and Emergence of Gene Therapy and Alternative Procoagulants
¸®¼Ä¡»ç
La Merie Publishing
»óǰÄÚµå
274454
¹ßÇà
2014³â 12¿ù
ÆäÀÌÁö Á¤º¸
210 Pages
°¡°Ý
US $ 2,795 ->
£Ü 3,355,000
1
2
´ÙÀ½
»ó±â ÀÚ·á ÀÌ¿ÜÀÇ
La Merie Publishing
ÀÚ·áµµ ÁÖ¹® °¡´ÉÇÏ´Ï
¹®ÀÇ
ÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.